AGMB Stock Forecast & Price Target

AgomAb Therapeutics is attractive because its lead asset ontunisertib has already shown a clean 12-week safety profile, gut-restricted pharmacokinetics, and meaningful exploratory efficacy in STENOVA, including a 31.8% conversion of non-passable strictures to passable versus 6.5% on placebo. The company’s outlook is strengthened by upcoming 2H26 catalysts, as the up-to-60-week OLE and the planned 52-week Ph2b NOV-ERA trial in roughly 320 FSCD patients should further de-risk registrational endpoint selection while testing higher doses up to 400 mg BID. Its second asset, AGMB-447, adds upside with lung-restricted ALK5 inhibition for IPF, supported by clean Phase 1 safety, strong target engagement, and a modeled rNPV framework that assigns $6/sh from cash and large potential sales contributions across FSCD and IPF.

AgomAb Therapeutics is viewed negatively because its lead assets remain highly speculative despite strong mechanistic rationale, with ontunisertib still needing to prove that TGFβ/ALK5 inhibition can translate into durable fibrosis reversal in FSCD rather than only modest symptomatic shifts. The company also faces a material safety and development overhang, since systemic ALK5 inhibition has been constrained by mechanism-based toxicities, while AGMB-447’s respiratory adverse events and discontinuations highlight tolerability risk even in inhaled programs. Fundamentally, the stock is further pressured by execution and financing risk, including probabilities of success of 45% for ontunisertib and 17.5% for AGMB-447, plus expected annual equity raises of €200-€250 million from 2028E-2032E that could dilute shareholders.